Navigation Links
KellBenx Secures Worldwide Agreement With Cedars-Sinai Medical Center for Biomarker Technology to Predict Premature Births
Date:4/18/2011

NEW YORK, April 18, 2011 /PRNewswire/ -- KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has signed an exclusive options agreement with Cedars-Sinai Medical Center to research a new blood test that could predict the risk of premature births early in pregnancy – or even before women become pregnant. Preterm delivery (PTD) is the leading cause of infant mortality in the world, causing up to 85 percent of all newborn deaths. KellBenx' worldwide license for Cedars-Sinai's diagnostic biomarker technology is the first step towards developing a marketable, minimally invasive test that can predict PTD and allow patients and doctors to make informed decisions about pregnancy in advance.

PTD occurs in about one-eighth of all pregnancies in the United States – more than a half million cases a year – but the primary current diagnostic testing for PTD risk is used only in the third trimester, to predict whether the patient will go into labor within the next two weeks.

"There is currently no test to predict the risk of PTD in future pregnancies of women who are not yet pregnant, and there is a tremendous need for such a test to identify women at high risk," said Hassan Bennani, MD., CEO of KellBenx. "With this agreement, KellBenx can begin the research process to turn this biomarker technology into a simple blood test that will help physicians focus on preventative strategies in these women and improve pregnancy outcomes. This is early-stage technology, but it has exciting possibilities for potentially reducing infant mortality."

The technology consists of a triple assay of biomarkers  that can measure a blood sample obtained from the prospective mother either before pregnancy or in the early stages to identify the potential for PTD.  The test could be repeated multiple times during pregnancy to track potential changes in risk as the pregnancy progresses.

About KellBenx

Founded in 2010, KellBenx, Inc. is a privately-held biotechnology company based in New York City. KellBenx is developing high value, innovative tests that leverage the ability to extract clinically relevant information from blood.  Our focus is to improve women's healthcare and one of our first tests is in the area of non-invasive prenatal diagnosis (NIPD) for genetic disorders. For more information, please call 631.643.2614 or visit www.kellbenx.com.


'/>"/>
SOURCE KellBenx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WNDM Secures Additional International Sales; $150 K in New Orders for 2011
2. BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
3. ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction
4. Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank
5. SeraCare Life Sciences Secures $20 Million Credit Facilities
6. Medizone International Secures $10,000,000 Funding Commitment
7. aTyr Pharma Secures $23M Financing From Top Tier Venture Investor
8. Omeros Secures $40 Million Committed Equity Financing Facility
9. SPO Medical Secures Agreement in Sleep Apnea Market
10. Biolaxy Secures IND Approval for Oral Insulin
11. Osteotech Secures 10-Year Tissue Supply Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... features a variety of fracture-specific plating options designed to address fractures of the ... fracture fixation solutions. , The Acumed Ankle Plating System 3 is composed of ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Lady had ... she tore her cruciate ligament in her left knee. Lady’s owner Hannah sought the ... central Florida board-certified veterinary surgeon, to repair her cruciate ligament and help with the ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
(Date:5/23/2016)... and LONDON , May 23, 2016 ... Frontage Boost Efficiency by 40% - Frontage Implement a ... Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... in the United States and ... be deployed across its laboratory facilities. In addition to serving as ...
Breaking Biology Technology:
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/10/2016)... India , March 10, 2016 ... a new market research report "Identity and Access Management ... & Audit, Compliance, and Governance), by Organization Size, by ... to 2020", published by MarketsandMarkets, The market is estimated ... USD 12.78 Billion by 2020, at a Compound Annual ...
Breaking Biology News(10 mins):